233 related articles for article (PubMed ID: 33144356)
1. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Antonelli A
J Clin Pathol; 2022 Jan; 75(1):39-44. PubMed ID: 33144356
[TBL] [Abstract][Full Text] [Related]
2. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett J; Xu B; Downes MR
J Clin Pathol; 2021 Jan; 74(1):53-57. PubMed ID: 32471889
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.
de Jong JJ; Stoop H; Boormans JL; van Leenders GJLH
Virchows Arch; 2021 Oct; 479(4):705-713. PubMed ID: 33909149
[TBL] [Abstract][Full Text] [Related]
4. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
5. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay.
Gupta G; Pasricha S; Kamboj M; Sharma A; Nayana NS; Durga G; Sharma A; Rawal S; Meh A
Indian J Pathol Microbiol; 2022; 65(4):839-843. PubMed ID: 36308190
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
[TBL] [Abstract][Full Text] [Related]
10. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.
Veerakumarasivam A; Scott HE; Chin SF; Warren A; Wallard MJ; Grimmer D; Ichimura K; Caldas C; Collins VP; Neal DE; Kelly JD
Clin Cancer Res; 2008 May; 14(9):2527-34. PubMed ID: 18451213
[TBL] [Abstract][Full Text] [Related]
11. Follicular dendritic cell sarcoma: clinicopathologic study of 15 cases with emphasis on novel expression of MDM2, somatostatin receptor 2A, and PD-L1.
Agaimy A; Michal M; Hadravsky L; Michal M
Ann Diagn Pathol; 2016 Aug; 23():21-8. PubMed ID: 27402219
[TBL] [Abstract][Full Text] [Related]
12. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
Gulinac M; Dikov D; Velikova T; Belovezhdov V
Ann Diagn Pathol; 2020 Dec; 49():151640. PubMed ID: 33069081
[TBL] [Abstract][Full Text] [Related]
13. The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features.
Bai Y; Wu X; Weng M; Han Q; Xu L; Chang C; Teng X
Indian J Pathol Microbiol; 2023; 66(4):702-707. PubMed ID: 38084519
[TBL] [Abstract][Full Text] [Related]
14. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Davick JJ; Frierson HF; Smolkin M; Gru AA
Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.
Mao S; Zhang J; Guo Y; Zhang Z; Wu Y; Zhang W; Wang L; Geng J; Yan Y; Yao X
Drug Des Devel Ther; 2019; 13():291-300. PubMed ID: 30666091
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Schulz GB; Todorova R; Braunschweig T; Rodler S; Volz Y; Eismann L; Pfitzinger P; Jokisch F; Buchner A; Stief C; Mayr D; Casuscelli J
Urol Oncol; 2021 Oct; 39(10):734.e1-734.e10. PubMed ID: 34261585
[TBL] [Abstract][Full Text] [Related]
20. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]